Forbes – High Drug Prices And Innovation
0
“The high cost of drugs has been a topic of debate among many people, including me and Dr. Peter Bach, the eminent Director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center (MSKCC). Essentially, Dr. Bach and I disagree on the importance of pricing on sustaining innovation in pharmaceutical drug R&D. This is an important debate to have, as all can benefit by understanding the issues at hand.”
Read more – Forbes